Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 101 | 2024 | 1467 | 16.930 |
Why?
|
Receptors, Antigen, T-Cell | 58 | 2024 | 2546 | 8.040 |
Why?
|
T-Lymphocytes | 90 | 2024 | 10175 | 6.560 |
Why?
|
Antigens, CD19 | 22 | 2024 | 424 | 4.260 |
Why?
|
Hematologic Neoplasms | 16 | 2024 | 1896 | 3.730 |
Why?
|
Antigens, Neoplasm | 16 | 2024 | 1985 | 2.110 |
Why?
|
B-Cell Maturation Antigen | 8 | 2024 | 149 | 1.980 |
Why?
|
Multiple Myeloma | 16 | 2024 | 5144 | 1.870 |
Why?
|
Glioblastoma | 10 | 2024 | 3481 | 1.820 |
Why?
|
Neoplasms | 28 | 2024 | 22131 | 1.800 |
Why?
|
Neurotoxicity Syndromes | 6 | 2024 | 301 | 1.790 |
Why?
|
Genetic Engineering | 9 | 2022 | 931 | 1.730 |
Why?
|
Tumor Microenvironment | 13 | 2024 | 3868 | 1.550 |
Why?
|
Immunotherapy | 19 | 2021 | 4642 | 1.540 |
Why?
|
Lymphoma, B-Cell | 5 | 2024 | 938 | 1.380 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2024 | 269 | 1.380 |
Why?
|
Recombinant Fusion Proteins | 10 | 2019 | 3730 | 1.190 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2024 | 3599 | 1.060 |
Why?
|
GPI-Linked Proteins | 4 | 2024 | 469 | 1.040 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2022 | 1639 | 1.030 |
Why?
|
Antigen-Presenting Cells | 7 | 2020 | 963 | 1.000 |
Why?
|
Antibodies, Bispecific | 2 | 2019 | 196 | 0.980 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2022 | 1551 | 0.920 |
Why?
|
Receptors, Antigen | 2 | 2014 | 51 | 0.900 |
Why?
|
Transduction, Genetic | 3 | 2020 | 901 | 0.810 |
Why?
|
Lymphoma | 3 | 2022 | 1899 | 0.810 |
Why?
|
Humans | 172 | 2024 | 760740 | 0.800 |
Why?
|
4-1BB Ligand | 2 | 2020 | 29 | 0.800 |
Why?
|
Bone Marrow Neoplasms | 1 | 2022 | 101 | 0.780 |
Why?
|
Cytotoxicity, Immunologic | 6 | 2021 | 1349 | 0.780 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2020 | 19 | 0.720 |
Why?
|
Accreditation | 1 | 2024 | 473 | 0.720 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2024 | 494 | 0.710 |
Why?
|
Endopeptidases | 1 | 2024 | 774 | 0.700 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1404 | 0.700 |
Why?
|
Lymphoma, Follicular | 2 | 2022 | 457 | 0.680 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.680 |
Why?
|
Lymphocyte Activation | 14 | 2021 | 5463 | 0.670 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2019 | 237 | 0.650 |
Why?
|
Research Personnel | 1 | 2024 | 588 | 0.640 |
Why?
|
Pancytopenia | 1 | 2019 | 102 | 0.630 |
Why?
|
Lentivirus | 2 | 2022 | 507 | 0.620 |
Why?
|
Pancreatic Neoplasms | 4 | 2024 | 5369 | 0.610 |
Why?
|
Tumor Burden | 1 | 2024 | 1892 | 0.610 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1405 | 0.580 |
Why?
|
T-Cell Antigen Receptor Specificity | 4 | 2019 | 84 | 0.580 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 212 | 0.570 |
Why?
|
Brain Neoplasms | 7 | 2021 | 9026 | 0.540 |
Why?
|
United States Food and Drug Administration | 2 | 2024 | 1661 | 0.530 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1051 | 0.530 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2016 | 69 | 0.520 |
Why?
|
Immunity, Cellular | 3 | 2020 | 1550 | 0.520 |
Why?
|
Flow Cytometry | 6 | 2024 | 5863 | 0.520 |
Why?
|
Lymphoma, T-Cell | 1 | 2018 | 304 | 0.510 |
Why?
|
Animals | 44 | 2024 | 168202 | 0.490 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 915 | 0.470 |
Why?
|
Immunologic Factors | 2 | 2020 | 1589 | 0.470 |
Why?
|
Cell Line, Tumor | 16 | 2024 | 16968 | 0.470 |
Why?
|
Sulfonamides | 1 | 2024 | 1977 | 0.460 |
Why?
|
Biological Products | 2 | 2022 | 912 | 0.450 |
Why?
|
Autoimmune Diseases | 3 | 2020 | 2238 | 0.440 |
Why?
|
Pyrazoles | 5 | 2022 | 2008 | 0.420 |
Why?
|
Apoptosis | 6 | 2024 | 9476 | 0.410 |
Why?
|
Virus Diseases | 2 | 2020 | 718 | 0.400 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2023 | 4365 | 0.400 |
Why?
|
Mice | 22 | 2024 | 81368 | 0.390 |
Why?
|
Pleural Neoplasms | 2 | 2014 | 609 | 0.380 |
Why?
|
Pyrimidines | 5 | 2022 | 3027 | 0.380 |
Why?
|
Adaptive Immunity | 1 | 2016 | 724 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9277 | 0.360 |
Why?
|
Mesothelioma | 2 | 2014 | 807 | 0.350 |
Why?
|
Receptors, Immunologic | 4 | 2017 | 1409 | 0.340 |
Why?
|
Mice, Inbred NOD | 5 | 2019 | 1827 | 0.320 |
Why?
|
Skin | 2 | 2019 | 4472 | 0.320 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4745 | 0.320 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2022 | 3611 | 0.320 |
Why?
|
K562 Cells | 3 | 2020 | 641 | 0.310 |
Why?
|
Cancer Vaccines | 2 | 2016 | 1037 | 0.310 |
Why?
|
Echovirus Infections | 1 | 2008 | 7 | 0.310 |
Why?
|
Enterovirus B, Human | 1 | 2008 | 47 | 0.300 |
Why?
|
Cytokines | 7 | 2023 | 7373 | 0.290 |
Why?
|
Leukemia, B-Cell | 2 | 2019 | 84 | 0.290 |
Why?
|
Cell Proliferation | 7 | 2019 | 10429 | 0.270 |
Why?
|
Clinical Trials as Topic | 8 | 2023 | 7995 | 0.270 |
Why?
|
Adoptive Transfer | 2 | 2022 | 818 | 0.270 |
Why?
|
Interleukin-7 | 2 | 2023 | 143 | 0.270 |
Why?
|
Tumor Escape | 2 | 2021 | 371 | 0.260 |
Why?
|
Anaphylaxis | 1 | 2013 | 757 | 0.250 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2024 | 5671 | 0.250 |
Why?
|
Single-Cell Analysis | 3 | 2021 | 2447 | 0.250 |
Why?
|
Signal Transduction | 6 | 2021 | 23415 | 0.250 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2019 | 3077 | 0.250 |
Why?
|
Antigens, CD7 | 1 | 2024 | 29 | 0.240 |
Why?
|
T-Lymphocyte Subsets | 4 | 2017 | 1797 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4570 | 0.230 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2812 | 0.230 |
Why?
|
Antigens, CD | 6 | 2024 | 3998 | 0.230 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5672 | 0.220 |
Why?
|
Bone Marrow | 4 | 2022 | 2909 | 0.220 |
Why?
|
Immunity, Innate | 1 | 2016 | 3045 | 0.220 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9171 | 0.220 |
Why?
|
Milk, Human | 1 | 2008 | 486 | 0.220 |
Why?
|
Virus Latency | 2 | 2023 | 354 | 0.210 |
Why?
|
Immune Tolerance | 4 | 2021 | 2298 | 0.210 |
Why?
|
Herpesvirus 6, Human | 1 | 2023 | 96 | 0.210 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2009 | 1779 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 410 | 0.200 |
Why?
|
Orbit | 4 | 2001 | 457 | 0.200 |
Why?
|
Immunomodulation | 2 | 2016 | 548 | 0.200 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 226 | 0.200 |
Why?
|
Infant, Premature, Diseases | 1 | 2008 | 710 | 0.200 |
Why?
|
Virus Activation | 1 | 2023 | 319 | 0.190 |
Why?
|
Single-Chain Antibodies | 2 | 2019 | 111 | 0.190 |
Why?
|
Tolnaftate | 1 | 2020 | 2 | 0.190 |
Why?
|
Burkitt Lymphoma | 1 | 2023 | 335 | 0.190 |
Why?
|
Immunologic Memory | 3 | 2021 | 1355 | 0.180 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2002 | 198 | 0.180 |
Why?
|
Graves Disease | 3 | 1999 | 238 | 0.180 |
Why?
|
Leukocytes, Mononuclear | 4 | 2022 | 1834 | 0.180 |
Why?
|
Gene Transfer Techniques | 3 | 2016 | 1202 | 0.180 |
Why?
|
Transgenes | 1 | 2024 | 1008 | 0.180 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2008 | 1351 | 0.180 |
Why?
|
HLA Antigens | 2 | 2003 | 1327 | 0.180 |
Why?
|
Inflammation | 2 | 2020 | 10759 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.170 |
Why?
|
Biopsy | 2 | 2024 | 6763 | 0.170 |
Why?
|
Ribonucleoproteins | 2 | 2021 | 360 | 0.170 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 120 | 0.170 |
Why?
|
Eyebrows | 2 | 2001 | 37 | 0.170 |
Why?
|
Zebrafish | 2 | 2021 | 3005 | 0.170 |
Why?
|
Mice, SCID | 3 | 2019 | 2625 | 0.170 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 117 | 0.170 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2002 | 581 | 0.160 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 1999 | 354 | 0.160 |
Why?
|
Women's Rights | 1 | 2019 | 65 | 0.160 |
Why?
|
Chemotactic Factors | 1 | 1999 | 197 | 0.160 |
Why?
|
HEK293 Cells | 4 | 2021 | 4269 | 0.160 |
Why?
|
Tumor Cells, Cultured | 5 | 2021 | 6126 | 0.160 |
Why?
|
Lymphocytes | 3 | 2024 | 2604 | 0.160 |
Why?
|
Macrophage Activation | 1 | 2022 | 552 | 0.160 |
Why?
|
Serine Endopeptidases | 1 | 2024 | 1022 | 0.160 |
Why?
|
Adult | 25 | 2024 | 220995 | 0.160 |
Why?
|
Aged | 22 | 2024 | 169092 | 0.160 |
Why?
|
Reference Standards | 1 | 2022 | 1003 | 0.160 |
Why?
|
Rhabdomyosarcoma | 1 | 2021 | 358 | 0.150 |
Why?
|
Codon, Nonsense | 1 | 2019 | 284 | 0.150 |
Why?
|
Craniotomy | 2 | 2001 | 741 | 0.150 |
Why?
|
Male | 31 | 2024 | 360402 | 0.150 |
Why?
|
Lymphoid Tissue | 1 | 2019 | 445 | 0.150 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2018 | 82 | 0.150 |
Why?
|
Open Reading Frames | 1 | 2021 | 813 | 0.150 |
Why?
|
Fatal Outcome | 2 | 2019 | 1835 | 0.140 |
Why?
|
Treatment Outcome | 12 | 2024 | 64572 | 0.140 |
Why?
|
Cell Death | 2 | 2022 | 1677 | 0.140 |
Why?
|
Prolactin | 1 | 1999 | 625 | 0.140 |
Why?
|
Granzymes | 1 | 2019 | 277 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2020 | 376 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2021 | 825 | 0.140 |
Why?
|
Bioreactors | 1 | 2018 | 246 | 0.140 |
Why?
|
E-Selectin | 1 | 2019 | 577 | 0.140 |
Why?
|
Gastrointestinal Tract | 1 | 2023 | 834 | 0.140 |
Why?
|
Protein Engineering | 3 | 2019 | 548 | 0.140 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1386 | 0.140 |
Why?
|
Orbital Neoplasms | 1 | 1999 | 222 | 0.140 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2023 | 1894 | 0.140 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2018 | 302 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2021 | 1372 | 0.140 |
Why?
|
Immunization | 1 | 2021 | 1217 | 0.140 |
Why?
|
Interferon-gamma | 3 | 2022 | 3145 | 0.140 |
Why?
|
Melphalan | 1 | 2018 | 420 | 0.130 |
Why?
|
Biotechnology | 1 | 2018 | 281 | 0.130 |
Why?
|
Adenine | 3 | 2017 | 985 | 0.130 |
Why?
|
Endonucleases | 1 | 2019 | 371 | 0.130 |
Why?
|
Middle Aged | 22 | 2024 | 220603 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2019 | 1788 | 0.130 |
Why?
|
Chimerism | 2 | 2014 | 155 | 0.130 |
Why?
|
Leukemia | 1 | 2023 | 1520 | 0.130 |
Why?
|
HIV-1 | 3 | 2022 | 6858 | 0.120 |
Why?
|
Peptides | 4 | 2021 | 4354 | 0.120 |
Why?
|
Skin Transplantation | 2 | 1999 | 1083 | 0.120 |
Why?
|
Exanthema | 1 | 2019 | 503 | 0.120 |
Why?
|
Female | 30 | 2024 | 392203 | 0.120 |
Why?
|
Fever | 2 | 2019 | 1618 | 0.120 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1348 | 0.120 |
Why?
|
Recurrence | 2 | 2024 | 8426 | 0.120 |
Why?
|
Glaucoma, Angle-Closure | 2 | 2001 | 190 | 0.110 |
Why?
|
Antibodies, Viral | 2 | 2022 | 3149 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1226 | 0.110 |
Why?
|
Histiocytosis | 1 | 2014 | 39 | 0.110 |
Why?
|
Eye Diseases | 1 | 1999 | 653 | 0.110 |
Why?
|
Hemangioma | 1 | 1999 | 727 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2018 | 1606 | 0.110 |
Why?
|
Sepsis | 1 | 2008 | 2585 | 0.110 |
Why?
|
Protein Binding | 3 | 2019 | 9345 | 0.110 |
Why?
|
Eyelids | 3 | 2001 | 278 | 0.110 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18220 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 509 | 0.110 |
Why?
|
Piperidines | 3 | 2017 | 1655 | 0.110 |
Why?
|
Compassionate Use Trials | 1 | 2013 | 50 | 0.110 |
Why?
|
Immunoglobulin Fragments | 1 | 2013 | 84 | 0.110 |
Why?
|
Dependovirus | 2 | 2009 | 712 | 0.110 |
Why?
|
Cell Line | 5 | 2019 | 15577 | 0.110 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13635 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1727 | 0.100 |
Why?
|
Schools, Medical | 1 | 2019 | 878 | 0.100 |
Why?
|
Surgery, Plastic | 1 | 1999 | 641 | 0.100 |
Why?
|
Induced Pluripotent Stem Cells | 2 | 2022 | 1851 | 0.100 |
Why?
|
Glycoproteins | 1 | 2019 | 2200 | 0.100 |
Why?
|
Disease Management | 2 | 2019 | 2506 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4512 | 0.100 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2191 | 0.100 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1614 | 0.100 |
Why?
|
Peptide Fragments | 1 | 2024 | 5109 | 0.100 |
Why?
|
Antigen Presentation | 3 | 2021 | 1250 | 0.100 |
Why?
|
Proteome | 1 | 2021 | 1857 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1378 | 0.090 |
Why?
|
Anterior Chamber | 2 | 2001 | 194 | 0.090 |
Why?
|
Demography | 1 | 2016 | 1643 | 0.090 |
Why?
|
Autoimmunity | 1 | 2019 | 1350 | 0.090 |
Why?
|
United States | 6 | 2024 | 72292 | 0.090 |
Why?
|
HIV Infections | 3 | 2022 | 17342 | 0.090 |
Why?
|
Light Coagulation | 1 | 1990 | 72 | 0.090 |
Why?
|
Leadership | 1 | 2019 | 1385 | 0.090 |
Why?
|
Ocular Hypotension | 1 | 1990 | 23 | 0.090 |
Why?
|
Phagocytosis | 2 | 2014 | 1526 | 0.080 |
Why?
|
Melanoma | 2 | 2022 | 5696 | 0.080 |
Why?
|
Risk Assessment | 2 | 2022 | 23974 | 0.080 |
Why?
|
Coculture Techniques | 3 | 2021 | 1336 | 0.080 |
Why?
|
Orbital Implants | 2 | 1999 | 21 | 0.080 |
Why?
|
Choroid Diseases | 1 | 1990 | 63 | 0.080 |
Why?
|
Cell Aggregation | 2 | 2019 | 239 | 0.080 |
Why?
|
Organ Transplantation | 1 | 2019 | 1157 | 0.080 |
Why?
|
Immune System | 1 | 2014 | 791 | 0.080 |
Why?
|
Antigens | 1 | 2014 | 1441 | 0.080 |
Why?
|
Patient Selection | 2 | 2020 | 4237 | 0.070 |
Why?
|
Muscle Proteins | 1 | 2013 | 1152 | 0.070 |
Why?
|
Administration, Oral | 1 | 2016 | 4010 | 0.070 |
Why?
|
Antibodies | 2 | 2014 | 2413 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12966 | 0.070 |
Why?
|
Critical Care | 1 | 2020 | 2691 | 0.070 |
Why?
|
Parvoviridae Infections | 1 | 2007 | 36 | 0.070 |
Why?
|
Receptors, Interleukin-6 | 2 | 2020 | 224 | 0.070 |
Why?
|
Retrospective Studies | 8 | 2024 | 80583 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2024 | 7847 | 0.070 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2222 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1008 | 0.070 |
Why?
|
Nanoparticles | 1 | 2018 | 1957 | 0.070 |
Why?
|
Cell Movement | 1 | 2018 | 5201 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6345 | 0.070 |
Why?
|
Gene Expression | 1 | 2019 | 7569 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 6030 | 0.070 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 3026 | 0.070 |
Why?
|
Protein Kinases | 1 | 2013 | 1606 | 0.070 |
Why?
|
Macrophages | 1 | 2021 | 5758 | 0.060 |
Why?
|
Capsid Proteins | 1 | 2009 | 464 | 0.060 |
Why?
|
Cell Differentiation | 2 | 2022 | 11512 | 0.060 |
Why?
|
Phenotype | 3 | 2021 | 16572 | 0.060 |
Why?
|
Glioma | 1 | 2020 | 3452 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2019 | 3842 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3527 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1600 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9417 | 0.060 |
Why?
|
Hepatocytes | 2 | 2009 | 1231 | 0.060 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 4849 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2023 | 39062 | 0.060 |
Why?
|
Capsid | 1 | 2007 | 433 | 0.060 |
Why?
|
Anemia | 1 | 2014 | 1504 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2016 | 5304 | 0.060 |
Why?
|
Ligands | 2 | 2019 | 3268 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11069 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3680 | 0.050 |
Why?
|
Transforming Growth Factor beta | 2 | 2023 | 1962 | 0.050 |
Why?
|
Roseolovirus Infections | 1 | 2023 | 49 | 0.050 |
Why?
|
Drug Approval | 2 | 2020 | 812 | 0.050 |
Why?
|
Glaucoma, Open-Angle | 1 | 1990 | 738 | 0.050 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2023 | 71 | 0.050 |
Why?
|
Genes, MHC Class I | 1 | 2003 | 235 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
Uveal Diseases | 1 | 2001 | 45 | 0.050 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 2112 | 0.050 |
Why?
|
Interleukin-15 | 2 | 2018 | 185 | 0.050 |
Why?
|
Biology | 1 | 2024 | 290 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2019 | 18937 | 0.050 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2021 | 86 | 0.050 |
Why?
|
Eye Enucleation | 2 | 1998 | 128 | 0.050 |
Why?
|
Membrane Microdomains | 1 | 2002 | 206 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8516 | 0.050 |
Why?
|
Orbital Pseudotumor | 1 | 2001 | 42 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2023 | 433 | 0.050 |
Why?
|
CD40 Ligand | 1 | 2003 | 521 | 0.050 |
Why?
|
N-Acetylglucosaminyltransferases | 1 | 2022 | 166 | 0.050 |
Why?
|
Ciliary Body | 1 | 2001 | 167 | 0.050 |
Why?
|
Diterpenes | 1 | 2021 | 170 | 0.040 |
Why?
|
Myocardium | 1 | 2013 | 4725 | 0.040 |
Why?
|
Prosthesis Implantation | 3 | 1999 | 591 | 0.040 |
Why?
|
Membrane Glycoproteins | 3 | 2003 | 3688 | 0.040 |
Why?
|
Caspases | 1 | 2023 | 878 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2004 | 1434 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2003 | 850 | 0.040 |
Why?
|
Time Factors | 3 | 2016 | 39908 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 302 | 0.040 |
Why?
|
Chromones | 1 | 1999 | 148 | 0.040 |
Why?
|
Microspheres | 1 | 2003 | 782 | 0.040 |
Why?
|
Cell Separation | 2 | 2002 | 1718 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2009 | 3392 | 0.040 |
Why?
|
NIH 3T3 Cells | 1 | 2021 | 669 | 0.040 |
Why?
|
Acidaminococcus | 1 | 2019 | 9 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 2019 | 114 | 0.040 |
Why?
|
Breast Feeding | 1 | 2008 | 1355 | 0.040 |
Why?
|
Azepines | 1 | 2021 | 329 | 0.040 |
Why?
|
RNA, Viral | 1 | 2008 | 2838 | 0.040 |
Why?
|
Cell Polarity | 1 | 2002 | 635 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 740 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 495 | 0.040 |
Why?
|
Fucose | 1 | 2019 | 122 | 0.040 |
Why?
|
Ubiquitination | 1 | 2023 | 1006 | 0.040 |
Why?
|
Remission, Spontaneous | 1 | 2019 | 384 | 0.040 |
Why?
|
Phthalazines | 1 | 2021 | 383 | 0.040 |
Why?
|
Mice, Inbred Strains | 1 | 2021 | 1759 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29601 | 0.040 |
Why?
|
Interleukin-6 | 2 | 2020 | 3205 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 59191 | 0.040 |
Why?
|
Child | 4 | 2023 | 80089 | 0.040 |
Why?
|
Blepharoplasty | 1 | 1999 | 61 | 0.040 |
Why?
|
Electroporation | 2 | 2014 | 233 | 0.040 |
Why?
|
Ethmoid Sinus | 1 | 1998 | 57 | 0.040 |
Why?
|
Frontal Sinus | 1 | 1998 | 51 | 0.040 |
Why?
|
Infant, Premature | 1 | 2008 | 2107 | 0.040 |
Why?
|
Mucocele | 1 | 1998 | 51 | 0.040 |
Why?
|
Silicones | 1 | 2018 | 228 | 0.040 |
Why?
|
Synthetic Biology | 1 | 2020 | 185 | 0.040 |
Why?
|
Polytetrafluoroethylene | 1 | 1998 | 245 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 1999 | 311 | 0.040 |
Why?
|
Drug Synergism | 2 | 1999 | 1756 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 597 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 458 | 0.040 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 209 | 0.040 |
Why?
|
Blood Proteins | 1 | 2002 | 1172 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2017 | 2425 | 0.040 |
Why?
|
Paranasal Sinus Diseases | 1 | 1998 | 121 | 0.040 |
Why?
|
Glycolysis | 1 | 2021 | 835 | 0.040 |
Why?
|
Histocompatibility Antigens | 2 | 2009 | 464 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2020 | 3820 | 0.030 |
Why?
|
Eyelid Diseases | 1 | 1999 | 157 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 1999 | 699 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2020 | 5239 | 0.030 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 3794 | 0.030 |
Why?
|
Permeability | 1 | 2018 | 721 | 0.030 |
Why?
|
Alleles | 2 | 2021 | 6861 | 0.030 |
Why?
|
Chemotaxis | 1 | 1999 | 598 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1098 | 0.030 |
Why?
|
Animals, Genetically Modified | 1 | 2021 | 1557 | 0.030 |
Why?
|
Morpholines | 1 | 1999 | 581 | 0.030 |
Why?
|
SOXB1 Transcription Factors | 1 | 2018 | 286 | 0.030 |
Why?
|
Bone Plates | 1 | 1999 | 464 | 0.030 |
Why?
|
Adolescent | 4 | 2021 | 88247 | 0.030 |
Why?
|
Triazoles | 1 | 2021 | 903 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2008 | 2149 | 0.030 |
Why?
|
MART-1 Antigen | 2 | 2007 | 63 | 0.030 |
Why?
|
Corneal Diseases | 1 | 2001 | 542 | 0.030 |
Why?
|
Cultural Diversity | 1 | 2019 | 369 | 0.030 |
Why?
|
Polyethylenes | 1 | 1998 | 290 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11107 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 1998 | 1031 | 0.030 |
Why?
|
Zebrafish Proteins | 1 | 2021 | 1013 | 0.030 |
Why?
|
Eye Movements | 1 | 1998 | 511 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4569 | 0.030 |
Why?
|
Cytoskeleton | 1 | 1999 | 1170 | 0.030 |
Why?
|
Viral Load | 1 | 2023 | 3325 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1864 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2214 | 0.030 |
Why?
|
HIV Antibodies | 1 | 2021 | 1302 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2509 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6370 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 74128 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2019 | 3088 | 0.030 |
Why?
|
HLA-A Antigens | 1 | 2013 | 223 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 58919 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1936 | 0.030 |
Why?
|
Neoplasm Proteins | 3 | 2013 | 3607 | 0.020 |
Why?
|
HIV Protease | 1 | 1992 | 97 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 1999 | 20988 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2022 | 6807 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2003 | 2722 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2017 | 1171 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 1608 | 0.020 |
Why?
|
Benzamides | 1 | 2017 | 1371 | 0.020 |
Why?
|
Pyrazines | 1 | 2017 | 1202 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 13442 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 1998 | 1269 | 0.020 |
Why?
|
Hypotension | 1 | 2017 | 879 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 1999 | 4802 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2521 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2013 | 927 | 0.020 |
Why?
|
Syndrome | 1 | 2017 | 3268 | 0.020 |
Why?
|
Intraocular Pressure | 2 | 2001 | 1294 | 0.020 |
Why?
|
Child, Preschool | 3 | 2021 | 42193 | 0.020 |
Why?
|
Prostate | 1 | 2018 | 1773 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 4937 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2391 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3370 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2014 | 13383 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1998 | 2160 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 3705 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3634 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 4 | 2001 | 20556 | 0.020 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2007 | 57 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 54364 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5822 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2008 | 26183 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2007 | 95 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15498 | 0.020 |
Why?
|
Solubility | 1 | 2009 | 1089 | 0.020 |
Why?
|
Epitopes | 1 | 2013 | 2501 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3743 | 0.020 |
Why?
|
Drug Resistance | 1 | 1992 | 1594 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2292 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4910 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12719 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 6988 | 0.020 |
Why?
|
Pregnancy | 1 | 2008 | 29869 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11118 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2013 | 1662 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 1998 | 3451 | 0.020 |
Why?
|
Cohort Studies | 2 | 2019 | 41464 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 1790 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2017 | 9526 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4172 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2014 | 12759 | 0.010 |
Why?
|
Indoles | 1 | 1992 | 1830 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14388 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9586 | 0.010 |
Why?
|
Protein Multimerization | 1 | 2009 | 982 | 0.010 |
Why?
|
Receptors, Fc | 1 | 2007 | 534 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13495 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22153 | 0.010 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2003 | 77 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4309 | 0.010 |
Why?
|
Ultrasonography | 2 | 2001 | 5965 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20077 | 0.010 |
Why?
|
Centrifugation, Density Gradient | 1 | 2002 | 299 | 0.010 |
Why?
|
Laser Therapy | 1 | 1990 | 1093 | 0.010 |
Why?
|
DNA, Recombinant | 1 | 2002 | 455 | 0.010 |
Why?
|
Cell Fractionation | 1 | 2002 | 249 | 0.010 |
Why?
|
RANK Ligand | 1 | 2003 | 318 | 0.010 |
Why?
|
Torsion Abnormality | 1 | 2001 | 91 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 1992 | 5780 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8652 | 0.010 |
Why?
|
Escherichia coli | 1 | 1992 | 4210 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22117 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2003 | 748 | 0.010 |
Why?
|
Histiocytes | 1 | 1998 | 98 | 0.010 |
Why?
|
Skin, Artificial | 1 | 1999 | 89 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2003 | 1079 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 3 | 2001 | 36401 | 0.010 |
Why?
|
Exophthalmos | 1 | 1998 | 97 | 0.010 |
Why?
|
Osseointegration | 1 | 1998 | 274 | 0.010 |
Why?
|
Postoperative Complications | 4 | 2001 | 15609 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2002 | 1888 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3798 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2002 | 2639 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4457 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 30015 | 0.010 |
Why?
|
Up-Regulation | 1 | 2002 | 4117 | 0.010 |
Why?
|
Decompression, Surgical | 1 | 1998 | 606 | 0.010 |
Why?
|
Arabinose | 1 | 1992 | 31 | 0.010 |
Why?
|
Rabbits | 1 | 1998 | 4770 | 0.010 |
Why?
|
Verapamil | 1 | 1992 | 242 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1992 | 851 | 0.010 |
Why?
|
Operon | 1 | 1992 | 372 | 0.010 |
Why?
|
Prosthesis Design | 1 | 1998 | 2114 | 0.010 |
Why?
|
Vinblastine | 1 | 1992 | 488 | 0.010 |
Why?
|
Collagen | 1 | 1999 | 2634 | 0.010 |
Why?
|
Wound Healing | 1 | 2001 | 2802 | 0.010 |
Why?
|
Vasoconstriction | 1 | 1992 | 592 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1992 | 2561 | 0.000 |
Why?
|
Calcium Channels | 1 | 1992 | 620 | 0.000 |
Why?
|
Fibroblasts | 1 | 1998 | 4140 | 0.000 |
Why?
|
Endoscopy | 1 | 1998 | 1851 | 0.000 |
Why?
|
Plasmids | 1 | 1992 | 2265 | 0.000 |
Why?
|
Blotting, Western | 1 | 1992 | 5034 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6074 | 0.000 |
Why?
|
Base Sequence | 1 | 1992 | 12420 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1992 | 17630 | 0.000 |
Why?
|
Calcium | 1 | 1992 | 5717 | 0.000 |
Why?
|
Rats | 1 | 1992 | 23716 | 0.000 |
Why?
|